Patents Assigned to Dompe' pha.r.ma S.p.A.
  • Publication number: 20090203740
    Abstract: 4-(trifluoromethanesulfonyloxyphenyl)propionic acid derivatives and pharmaceutical composition containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, these metabolites are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
    Type: Application
    Filed: March 21, 2005
    Publication date: August 13, 2009
    Applicant: Dompe' pha.r.ma S.p.A
    Inventors: Marcello Allegretti, Maria Candida Cesta, Riccardo Bertini, Marco Mosca, Francesco Colotta
  • Publication number: 20090030083
    Abstract: N-(2-aryl-propionyl)-sulfonamides of general formula (I): are useful in the treatment of spinal cord injury.
    Type: Application
    Filed: March 17, 2005
    Publication date: January 29, 2009
    Applicant: Dompe' pha.r.ma S.p.A
    Inventors: Riccardo Bertini, Francesco Colotta
  • Publication number: 20080312293
    Abstract: The present invention relates to selected (R)-2-phenyl-propionamides and (R)-2-phenyl-sulfonamides with a hydrogen bond acceptor atom/group in a well defined position in the chemical space. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the invention absolutely lack of CXCL8 inhibitory activity. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.
    Type: Application
    Filed: December 13, 2005
    Publication date: December 18, 2008
    Applicant: Dompe' PHA.R.MA.S.P.A.
    Inventors: Marcello Allegretti, Riccardo Bertini, Andrea Beccari, Alessio Moriconi, Andrea Aramini, Cinzia Bizzarri, Francesco Colotta
  • Publication number: 20080045522
    Abstract: (R)-2-Arylpropionamide compounds of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear leukocytes (leukocytes PMN) and of monocytes at the inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use in the inhibition of the chemotaxis of neutrophils and monocytes induced by the C5a fraction of the complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of PMN leukocytes.
    Type: Application
    Filed: August 13, 2007
    Publication date: February 21, 2008
    Applicant: Dompe pha.r.ma S.p.A.
    Inventors: Marcello ALLEGRETTI, Riccardo Bertini, Valerio Berdini, Cinzia Bizzarri, Maria Cesta, Vito Di Cioccio, Gianfranco Caselli, Francesco Colotta, Carmelo Gandolfi, Janete Gandolfi, Giulio Gandolfi, Maria Gandolfi, Arrigo Gandolfi
  • Publication number: 20070155717
    Abstract: Amidines and derivatives thereof of formula (I) are described. The process for their preparation and pharmaceutical compositions thereof are also described. The amidines of the invention are useful in the inhibition of chemotaxis of neutrophils induced by IL-8. The compounds of the invention are used in the treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
    Type: Application
    Filed: September 16, 2004
    Publication date: July 5, 2007
    Applicant: Dompe pha.r.ma S.p.A
    Inventors: Marcello Allegretti, Maria Cesta, Giuseppe Nano, Riccardo Bertini, Cinzia Bizzarri, Francesco Colotta
  • Patent number: 7217707
    Abstract: N-(2-aminoaryl-propionyl)-amides of formula (1) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The amides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear neutrophils (leukocytes PMN) at the inflammatory sites. In particular, the invention relates to the R enantiomers of 2-(aminoaryl)-propionyl amides of formula (1) for use in the ihibition of the chemotaxis of neutrophils induced by IL-8. The compounds of the invention are used in the treatment of psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, and rheumatoid arthritis.
    Type: Grant
    Filed: April 11, 2001
    Date of Patent: May 15, 2007
    Assignee: Dompe S.p.A.
    Inventors: Marcello Allegretti, Riccardo Bertini, Cinzia Bizzarri, Vilma Sabbatini, Ginfranco Caselli, Maria Candida Cesta, Janete Peloia Barroso Gandolfi, legal representative, Giulio Agostino Gandolfi, legal representative, Maria Carla Gandolfi, legal representative, Arrigo Aldo Gandolfi, legal representative, Francesco Colotta, Carmelo Gandolfi, deceased
  • Publication number: 20070036747
    Abstract: Combined pharmaceutical preparation containing G-CSF and P1GF as the active substances, are useful in the mobilization of blood stem cells in a patient or subject in need thereof.
    Type: Application
    Filed: July 23, 2004
    Publication date: February 15, 2007
    Applicant: Dompe S.p.A.
    Inventors: Alessandro Gianni, Carmelo Carlo-Stella, Francesco Colotta
  • Patent number: 7175886
    Abstract: An apparatus is described for micron and submicron particles formation of a substance using the GAS process, comprising a particles formation vessel (22) and means for introducing a solution of the substance and a supercritical fluid into the particles formation vessel (22), wherein said means comprise a nozzle (27) having a central orifice (39) serving to carry a flow of solution, and a plurality of separate outer orifices (41) serving to carry a flow of pure supercritical fluid or a flow of supercritical fluid mixed with a modifier, such that the solvent is extracted from the solution by the supercritical fluid and precipitation of micron and submicron particles occurs. Also a process is described, carried out with such an apparatus.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: February 13, 2007
    Assignee: Dompe' pha.r.ma S.p.A.
    Inventors: Giovanni Del Re, Matteo Putrignano, Gabriele Di Giacomo, Cesare Di Palma
  • Publication number: 20060258730
    Abstract: Selected sulfonic acids, their derivatives and pharmaceutical compositions containing such compounds are useful in inhibiting the chernotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CX-CR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, the selected sulfonic acids and their derivativas are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
    Type: Application
    Filed: March 11, 2004
    Publication date: November 16, 2006
    Applicant: Dompe S.p.A.
    Inventors: Marcello Allegretti, Andrea Aramini, Maria Cesta, Riccardo Bertini, Cinzia Bizzarri, Francesco Colotta
  • Publication number: 20060140816
    Abstract: A process for the sterilization of water insoluble solid medicinal substances is described. The process provides the sterilization of drug substances, which are suitable for pulmonary administration. In particular, the process is used in industrial plants for the production of formulations of sterile glucocorticoids for inhalation delivery, so as to avoid any modifications in particle size distribution and in the impurities profile of the drug. the process is carried out by heating a mixture of micronized glucocorticoid and purified water only, preferably at a temperature of about 120° C. for 20 minutes. The process is particularly efficient and economic for the steam sterilization of beclomethasone dipropionate in formulations for pulmonary delivery.
    Type: Application
    Filed: March 2, 2004
    Publication date: June 29, 2006
    Applicant: Dompe S.p.A
    Inventors: Marco Gentile, Maria Dragani, Marco Dell'uomo
  • Patent number: 6887903
    Abstract: The compounds of formula 1 wherein R and R2 are as defined in the disclosure, are useful in the prevention and treatment of tissue damage due to exacerbated recruitment of polymorphonuclear neutrophils (PMN leukocytes) at the inflammatory sites.
    Type: Grant
    Filed: October 14, 1999
    Date of Patent: May 3, 2005
    Assignee: Dompe S.p.A.
    Inventors: Riccardo Bertini, Cinzia Bizzarri, Vilma Sabbatini, Gianfranco Caselli, Marcello Allegretti, Maria Candida Cesta, Carmelo Gandolfi, Marco Mantovanini, Francesco Colotta, Stefano Porzio
  • Publication number: 20050080067
    Abstract: (R)-2-Arylpropionamide compounds of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear leukocytes (leukocytes PMN) and of monocytes at the inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use in the inhibition of the chemotaxis of neutrophils and monocytes induced by the C5a fraction of the complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of PMN leukocytes.
    Type: Application
    Filed: February 25, 2002
    Publication date: April 14, 2005
    Applicant: Dompe S.p A.
    Inventors: Marcello Allegretti, Riccardo Bertini, Valerio Berdini, Cinzia Bizzarri, Maria Cesta, Vito Di Cioccio, Gianfranco Caselli, Francesco Colotta
  • Patent number: 6770781
    Abstract: A process for the preparation of meta or para-substituted &agr;-arylalkanoic acids of formula (I) wherein R and R1 are as defined in the disclosure.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: August 3, 2004
    Assignee: Dompe′ S.p.A
    Inventors: Marcello Allegretti, Maria Candida Cesta, Marco Mantovanini, Luca Nicolini
  • Patent number: 6730657
    Abstract: Recombinant proteins derived by recombination of structural domains obtained from alpha and beta subunits of HGF and/or MSP growth factors. These recombinant proteins contain domains selected from HGF and MSP, and are useful to protect cells, including differentiated cell elements of liver, kidney, and mucosa of the gastorenteral tract, from death (i.e., apoptosis) induced by chemotherapeutics.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: May 4, 2004
    Assignee: Dompe' S.p.A.
    Inventors: Enzo Medico, Paolo Michieli, Chiara Colessi, Gianfranco Caselli, Paolo Comoglio
  • Publication number: 20030216392
    Abstract: The compounds of formula 1, 1
    Type: Application
    Filed: June 13, 2003
    Publication date: November 20, 2003
    Applicant: Dompe S.p.A.
    Inventors: Riccardo Bertini, Cinzia Bizzarri, Vilma Sabbatini, Gianfranco Caselli, Marcello Allegretti, Maria Candida Cesta, Carmelo Gandolfi, Marco Mantovanini, Francesco Colotta, Stefano Porzio
  • Patent number: 6551991
    Abstract: Recombinant proteins deriving from recombination of structural domains deriving from the &agr; subunits of HGF and/or MSP growth factors. The recombinant proteins of the present invention have biological activity, and protect cells from death (apoptosis) induced by chemotherapeutic drugs. These molecules can conveninently be used to prevent or to treat the toxic side effects of chemotherapeutic agents used in cancer therapy.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: April 22, 2003
    Assignee: Dompe' S.p.A.
    Inventors: Enzo Medico, Paolo Michieli, Chiara Collesi, Gianfranco Caselli, Paolo Comoglio
  • Patent number: 6069172
    Abstract: A new use of the enantiomer (R)-ketoprofen and of its salts with suitable organic and inorganic bases in the therapy of neutrophil-dependent diseases and phlogistic processes is described as well as pharmaceutical preparations containing such compounds and useful for oral, parenteral or topical administration.
    Type: Grant
    Filed: January 27, 1999
    Date of Patent: May 30, 2000
    Assignee: Dompe' SpA
    Inventors: Riccardo Bertini, Cinzia Bizzarri, Laura Brandolini, Gabriella Melillo, Gianfranco Caselli, Gaetano Clavenna
  • Patent number: 6030949
    Abstract: The present invention refers to the use of Macrophage Stimulating Protein (MSP) for the preparation of a medicament for the treatment of pathologies of the central and peripheral nervous system of traumatic, infectious or inflammatory origin.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: February 29, 2000
    Assignee: Dompe S.p.A.
    Inventors: Paolo Comoglio, Alessandro Vercelli, Francesco Galimi, Gianfranco Caselli, Maria Cristina Stella
  • Patent number: 5968501
    Abstract: Hepatocyte growth factor stimulates proliferation and differentiation of hematopoietic cells, most preferably burst-forming unit-erythroid cells. The hepatocyte growth factor may be obtained from cells transformed with human gene sequences coding therefor. Pharmaceutical compositions useful to induce the proliferation and differentiation of hematopoietic cells may contain hepatocyte growth factor as an active principle in admixture with a suitable carrier. The pharmaceutical compositions may additionally contain stem cell factor as an active principle.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: October 19, 1999
    Assignee: Dompe S.p.A.
    Inventor: Paolo Comoglio
  • Patent number: 5922573
    Abstract: DNA molecules that code for IL-1 antagonists with improved biological activity arc described. DNA molecules coding for improved IL-1 antagonists inserted into expression vectors and host cells transformed with the said vectors containing the DNA coding for improved IL-1 antagonists and a method for the production of improved IL-1 antagonists in essentially pure form are also described. Preparations that can be injected or can be administered by some other route, consisting of a pharmaceutical preparation of the said mutants, are particularly useful as drugs in the field of therapy.
    Type: Grant
    Filed: April 15, 1997
    Date of Patent: July 13, 1999
    Assignee: Dompe' S.p.A.
    Inventors: Diana Boraschi, Paola Bossu, Paolo Ruggiero, Giovanni Macchia, Aldo Tagliabue, Francesco Frigerio, Renata Grifantini, Gianni Frascotti, Guido Grandi